https://www.openbell.ai/ 2026-10-16T19:37:07.515Z hourly 1.0 https://www.openbell.ai/support 2026-10-16T19:37:07.515Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-16T19:37:07.515Z monthly 0.5 https://www.openbell.ai/terms 2026-10-16T19:37:07.515Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-16T19:37:07.515Z hourly 0.8 https://www.openbell.ai/news/LRCX:1792179009428 2026-10-16T19:30:09.428Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Quarterly-Results-Sales-Profits-Earnings.jpg?width=250&height=187 Lam Research Could Swing $28.6 Billion After Earnings Lam Research Corp is set to report its first quarter of 2027 results on Wednesday, with Wall Street expecting earnings per share (EPS) of $2.17 on revenue of $8.14 billion, up from $1.26 EPS on $5.32 billion a year ago. The options market is pricing in a 7.95% move, indicating a potential $28.6 billion swing in market value for the company, which has a market capitalization of $359 billion. Despite a strong year-to-date performance with shares up 49.9%, the stock is currently trading 2.0% below the 200-day moving average and about 37% below its 52-week high of $438.50. https://www.openbell.ai/news/SFTBY:1792178591252 2026-10-16T19:23:11.252Z daily 0.9 https://cdn.brandfetch.io/SFTBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'SoftBank Is Said to Weigh Buying Top US Security Firm Allied' - Bloomberg News SoftBank is reportedly considering the acquisition of Allied Universal, the largest security firm in the United States. This potential move reflects SoftBank's strategy to expand its portfolio in the security sector. The deal could significantly impact both companies and the broader security industry, although specific financial details have not been disclosed. https://www.openbell.ai/news/RKLB:1792178493989 2026-10-16T19:21:33.989Z daily 0.9 https://cdn.brandfetch.io/RKLB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of space-related companies are trading lower, possibly as Rocket Lab extended losses, falling over 8% after an analyst cut its price target following a delay to its Neutron rocket’s first launch, weighing on peers. openbell Financial News https://www.openbell.ai/news/KO:1792178317876 2026-10-16T19:18:37.876Z daily 0.9 https://cdn.brandfetch.io/KO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Maintains Overweight on Coca-Cola, Raises Price Target to $98 Barclays analyst Lauren Lieberman has reiterated an Overweight rating on Coca-Cola (NYSE: KO) and increased the price target from $93 to $98. This adjustment reflects a positive outlook for the company's stock performance. https://www.openbell.ai/news/TSM:1792178208799 2026-10-16T19:16:48.799Z daily 0.9 https://cdn.brandfetch.io/TSM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Maintains Overweight on Taiwan Semiconductor, Raises Price Target to $670 Barclays analyst Simon Coles has maintained an Overweight rating on Taiwan Semiconductor (NYSE: TSM) and raised the price target from $665 to $670. This adjustment reflects a positive outlook for the company in the semiconductor industry. https://www.openbell.ai/news/USO:1792178193098 2026-10-16T19:16:33.098Z daily 0.9 https://cdn.brandfetch.io/USO/w/400/h/400?c=1idopYfmtR7ZKg8QMud The Hormuz Letter Posts On X "BREAKING: UKMTO says the majority of vessels struck by Iran are refusing to report to it, meaning the true number of attacks on vessels is at least double what has been recorded..." "That puts the floor at nearly 60 vessels struck by Iran since October 1, against the roughly 30 UKMTO has confirmed. The strength of the language points to a real figure in the 70 to 100 range. October was already the highest month of the war on the reported number alone." The UK Maritime Trade Operations (UKMTO) reports that the actual number of vessels attacked by Iran is likely at least double the confirmed figure, indicating nearly 60 vessels have been struck since October 1, compared to approximately 30 confirmed. This suggests the true number could range between 70 to 100 attacks. October has already been noted as the month with the highest reported attacks in the ongoing conflict. https://www.openbell.ai/news/MDLZ:1792177602450 2026-10-16T19:06:42.450Z daily 0.9 https://cdn.brandfetch.io/MDLZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Maintains Overweight on Mondelez International, Raises Price Target to $72 Barclays analyst Andrew Lazar has maintained an Overweight rating on Mondelez International (NASDAQ: MDLZ) and increased the price target from $70 to $72. This adjustment reflects a positive outlook for the company's stock performance. https://www.openbell.ai/news/IFF:1792177379975 2026-10-16T19:02:59.975Z daily 0.9 https://cdn.brandfetch.io/IFF/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Maintains Overweight on Intl Flavors & Fragrances, Raises Price Target to $105 Barclays analyst Lauren Lieberman has maintained an Overweight rating on International Flavors & Fragrances (NYSE: IFF) and raised the price target from $96 to $105. This adjustment reflects a positive outlook for the company in the market. https://www.openbell.ai/news/IBKR:1792177306896 2026-10-16T19:01:46.896Z daily 0.9 https://cdn.brandfetch.io/IBKR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Maintains Overweight on Interactive Brokers Group, Raises Price Target to $117 Barclays analyst Benjamin Budish has reaffirmed an Overweight rating on Interactive Brokers Group (NASDAQ: IBKR) and increased the price target from $115 to $117. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/HLT:1792177091585 2026-10-16T18:58:11.585Z daily 0.9 https://cdn.brandfetch.io/HLT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Maintains Overweight on Hilton Worldwide Holdings, Raises Price Target to $384 Barclays analyst Brandt Montour has maintained an Overweight rating on Hilton Worldwide Holdings (NYSE: HLT) and raised the price target from $368 to $384. This adjustment reflects a positive outlook for the company in the market. https://www.openbell.ai/news/HAIN:1792177000670 2026-10-16T18:56:40.670Z daily 0.9 https://cdn.brandfetch.io/HAIN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Maintains Underweight on Hain Celestial Group, Lowers Price Target to $0.3 Barclays analyst Andrew Lazar has maintained an Underweight rating on Hain Celestial Group (NASDAQ: HAIN) and has reduced the price target from $0.5 to $0.3. This adjustment reflects a more cautious outlook on the company's performance. https://www.openbell.ai/news/FMC:1792176933329 2026-10-16T18:55:33.329Z daily 0.9 https://cdn.brandfetch.io/FMC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Maintains Underweight on FMC, Lowers Price Target to $4 Barclays analyst Benjamin Theurer has maintained an Underweight rating on FMC (NYSE:FMC) and reduced the price target from $9 to $4. This adjustment reflects a more cautious outlook on the company's performance. https://www.openbell.ai/news/SMCI:1792176489496 2026-10-16T18:48:09.496Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Supermicro.jpg?width=250&height=187 Super Micro Finally Names a CFO, Nearly Two Years After an Accounting Review Prompted the Search Super Micro Computer Inc. has appointed Mark Long as its new Chief Financial Officer, effective immediately, nearly two years after initiating the search due to accounting scrutiny. Long replaces David Weigand, who will now focus on optimizing the business. The company's stock fell nearly 10% following the announcement, and it faces ongoing challenges related to governance and export controls, while strong demand for AI infrastructure supports a revenue outlook of $65 billion to $72 billion for fiscal 2027. https://www.openbell.ai/news/LITE:1792176328568 2026-10-16T18:45:28.568Z daily 0.9 https://cdn.brandfetch.io/LITE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of fiber-optic connectivity companies are trading lower as elevated Treasury yields and increased Fed rate-hike expectations following this week's latest inflation data weigh on technology stocks. Elevated borrowing costs could pressure AI infrastructure spending plans, raising concerns about future demand for fiber-optic equipment and connectivity solutions. openbell Financial News https://www.openbell.ai/news/NVDA:1792175641574 2026-10-16T18:34:01.574Z daily 0.9 https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud SemiAnalysis Pots On X "SHOCKING: We have confirmed that multiple Neoclouds have been refused access to GTC Berlin due to them adding AMD GPUs, TPUs, and other chips to their cloud offerings. Note that this doesn't apply to hyperscalers, as they have more buying power. But for neoclouds, executives feel NVIDIA has been using high-pressure tactics to keep them NVIDIA-only...." Multiple neoclouds have been denied access to GTC Berlin after incorporating AMD GPUs, TPUs, and other chips into their offerings, as confirmed by SemiAnalysis. This situation does not affect hyperscalers, who possess greater buying power. Executives from the neoclouds allege that NVIDIA is employing high-pressure tactics to maintain its exclusivity in the market. https://www.openbell.ai/news/AGCC:1792175365175 2026-10-16T18:29:25.175Z daily 0.9 https://cdn.brandfetch.io/AGCC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Agencia Comercial Spirits shares are trading higher after the company announced its subsidiary AGCC Singapore entered into a long-term AI computing agreement in Indonesia. openbell Financial News https://www.openbell.ai/news/DAL:1792175308531 2026-10-16T18:28:28.531Z daily 0.9 https://cdn.brandfetch.io/DAL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of airline companies are trading lower amid a rise in oil prices. Elevated fuel costs and rising Treasury yields are fueling concerns about persistent inflation and increased financing costs, which could pressure airline profitability and weigh on passenger demand. openbell Financial News https://www.openbell.ai/news/AAL:1792175062988 2026-10-16T18:24:22.988Z daily 0.9 https://cdn.brandfetch.io/AAL/w/400/h/400?c=1idopYfmtR7ZKg8QMud American Airlines Group shares are trading lower after UBS lowered its price target on the stock from $17 to $16. openbell Financial News https://www.openbell.ai/news/WSC:1792174927895 2026-10-16T18:22:07.895Z daily 0.9 https://cdn.brandfetch.io/WSC/w/400/h/400?c=1idopYfmtR7ZKg8QMud UBS Maintains Neutral on WillScot Holdings, Lowers Price Target to $18 UBS analyst Joshua Chan has maintained a Neutral rating on WillScot Holdings (NASDAQ: WSC) and has lowered the price target from $29 to $18. This adjustment reflects a change in the analyst's outlook on the company's stock performance. https://www.openbell.ai/news/AVBP:1792174901266 2026-10-16T18:21:41.266Z daily 0.9 https://cdn.brandfetch.io/AVBP/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target BTIG analyst Jeet Mukherjee has reiterated a Buy rating on ArriVent BioPharma (NASDAQ: AVBP) and has maintained a price target of $29 for the stock. https://www.openbell.ai/news/RHHBY:1792174844706 2026-10-16T18:20:44.706Z daily 0.9 https://cdn.brandfetch.io/RHHBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy Roche Holdings AG received FDA approval for Enspryng (satralizumab), the first at-home subcutaneous treatment for thyroid eye disease. The approval was based on Phase 3 SatraGO trials, where Enspryng showed a 52.9% proptosis response rate and a 60.7% reduction in double vision among treated patients, significantly outperforming the placebo group. Following the announcement, Roche's stock price increased by 0.93% to $57.31. https://www.openbell.ai/news/SHOP:1792174844271 2026-10-16T18:20:44.271Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/The-Shopify-Trade.jpg?width=250&height=187 Shopify Price Hikes Signal Pricing Power as JPMorgan Keeps $200 Bullish Target Shopify Inc. has increased the pricing for its Grow and Advanced plans by 13% ($10) and 20% ($60), respectively, as reported by JPMorgan. Analyst Bryan Smilek estimates these changes could generate over $40 million in incremental annualized revenue, assuming a global rollout. Despite a recent 4.51% drop in stock price to $170.11, JPMorgan maintains a bullish price target of $200, reflecting confidence in Shopify's pricing power and market position. Wall Street anticipates third-quarter earnings of 46 cents per share and revenue of $3.75 billion, up from $2.84 billion a year earlier. https://www.openbell.ai/news/EW:1792174843966 2026-10-16T18:20:43.966Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Irvine--California---7-May-2023-Edwards-.jpg?width=250&height=187 FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death The FDA has issued a high-risk alert regarding a recall of specific lots of Edwards Lifesciences Corp.'s Commander M delivery systems after reports of balloons bursting during procedures, which led to one patient death and a serious injury. The company has advised customers to immediately stop using the affected products and remove them from inventory. As a result of the recall, Edwards Lifesciences' stock price fell by 0.86% to $87.34. https://www.openbell.ai/news/RHHBY:1792174824888 2026-10-16T18:20:24.888Z daily 0.9 https://cdn.brandfetch.io/RHHBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy Roche Holdings AG received FDA approval for Enspryng (satralizumab), the first at-home subcutaneous treatment for thyroid eye disease. The approval was based on Phase 3 SatraGO trials, where the SatraGO-2 trial showed a 52.9% proptosis response rate in treated patients compared to 23.4% for placebo, and a 60.7% reduction in double vision versus 25.8% in the control group. Following the announcement, Roche's stock price increased by 0.93% to $57.31. https://www.openbell.ai/news/RHHBY:1792174788907 2026-10-16T18:19:48.907Z daily 0.9 https://cdn.brandfetch.io/RHHBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy Roche Holdings AG has received FDA approval for Enspryng (satralizumab), the first at-home subcutaneous therapy for thyroid eye disease. The approval is based on the Phase 3 SatraGO trials, where the SatraGO-2 trial showed a 52.9% proptosis response rate in treated patients, compared to 23.4% for the placebo. Roche shares rose 0.93% to $57.31 following the announcement. https://www.openbell.ai/news/EW:1792174786788 2026-10-16T18:19:46.788Z daily 0.9 https://cdn.brandfetch.io/EW/w/400/h/400?c=1idopYfmtR7ZKg8QMud FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death Edwards Lifesciences Corp. (NYSE: EW) has issued a recall for specific lots of its Commander M delivery systems following reports of balloons bursting during procedures, which have resulted in one patient death and a serious injury. The FDA has flagged this as a high-risk alert, advising customers to stop using the affected products immediately. As a result of the recall, Edwards Lifesciences shares fell 0.86% to $87.34. https://www.openbell.ai/news/TSLA:1792174783009 2026-10-16T18:19:43.009Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Elon-Musk.jpg?width=250&height=187 Tesla's Flying Roadster Sends Delivery Odds Tumbling Despite Spectacular Demo Tesla Inc. (NASDAQ: TSLA) showcased its long-awaited flying Roadster, but delivery predictions have significantly decreased, with market odds for delivery by the end of 2027 dropping from 33% to around 10%. Production is not set to begin until 2028, and the company continues to accept $50,000 reservations without a guaranteed delivery date. Following the demonstration, Tesla shares initially rose over 4% in premarket trading but later fell below the previous day's closing price. https://www.openbell.ai/news/RHHBY:1792174766680 2026-10-16T18:19:26.680Z daily 0.9 https://cdn.brandfetch.io/RHHBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy Roche Holdings AG received FDA approval for Enspryng (satralizumab), the first at-home subcutaneous treatment for thyroid eye disease. The approval was based on Phase 3 SatraGO trials, where the SatraGO-2 trial showed a 52.9% proptosis response rate in treated patients, compared to 23.4% for placebo, and a 60.7% reduction in double vision versus 25.8% in the control group. Following the announcement, Roche's shares rose by 0.93% to $57.31. https://www.openbell.ai/news/AMD:1792174760895 2026-10-16T18:19:20.895Z daily 0.9 https://cdn.brandfetch.io/AMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of semiconductor and chip companies are trading lower as rising inflation concerns and elevated energy prices fuel expectations for further Fed rate hikes. Elevated borrowing costs could pressure semiconductor manufacturing and AI infrastructure investments while straining customer budgets. The Philadelphia Semiconductor Index (SOX) has declined for seven consecutive trading sessions, matching its longest losing streak since the 2008 financial crisis. openbell Financial News https://www.openbell.ai/news/EW:1792174753707 2026-10-16T18:19:13.707Z daily 0.9 https://cdn.brandfetch.io/EW/w/400/h/400?c=1idopYfmtR7ZKg8QMud FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death The FDA issued a high-risk recall alert for specific lots of Edwards Lifesciences Corp.'s Commander M delivery systems after reports of balloons bursting during procedures, leading to one death and a serious injury. The devices are used to implant replacement mitral heart valves without open-chest surgery, and the company has instructed customers to stop using the affected lots immediately. As a result of the recall, Edwards Lifesciences shares fell by 0.86% to $87.34. https://www.openbell.ai/news/GNRC:1792174565439 2026-10-16T18:16:05.439Z daily 0.9 https://cdn.brandfetch.io/GNRC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of data center infrastructure-related companies are trading lower as elevated oil prices and stronger-than-expected inflation data this week fuel concerns that interest rates will remain higher for longer. Elevated financing costs could slow investment in data centers and power infrastructure, weighing on demand for electrical equipment and HVAC systems. openbell Financial News https://www.openbell.ai/news/BA:1792174030264 2026-10-16T18:07:10.264Z daily 0.9 https://cdn.brandfetch.io/BA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reuters Reported Federal Aviation Administration Set To Approve Boeing 737 MAX 10 As Soon As Next Week openbell Financial News https://www.openbell.ai/news/SHLS:1792173674712 2026-10-16T18:01:14.712Z daily 0.9 https://cdn.brandfetch.io/SHLS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shoals Technologies Group shares are trading lower after Mizuho lowered its price target on the stock from $11 to $10. openbell Financial News https://www.openbell.ai/news/MAN:1792173427334 2026-10-16T17:57:07.334Z daily 0.9 https://cdn.brandfetch.io/MAN/w/400/h/400?c=1idopYfmtR7ZKg8QMud ManpowerGroup shares are trading lower after multiple analysts lowered their respective price targets on the stock. openbell Financial News https://www.openbell.ai/news/COP:1792173259912 2026-10-16T17:54:19.912Z daily 0.9 https://cdn.brandfetch.io/COP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of oil and gas-related companies are trading higher after reports suggesting that Iran placed its armed forced on high alert for 72 hours. Also, reports of an attempted Houthi strike on Saudi Arabia's Red Sea port of Yanbu and another Iranian strike on a vessel near the Strait of Hormuz may fuel concerns that high energy prices may persist and benefit the sector. openbell Financial News https://www.openbell.ai/news/AAPG:1792173144932 2026-10-16T17:52:24.932Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Acute-Myeloid-Leukemia-Is-A-Subtype-Of-B.jpg?width=250&height=187 Ascentage Pharma Stock Could More Than Double: Analyst Ascentage Pharma Group International (NASDAQ: AAPG) has been given an Outperform rating by analyst Alethia Young from William Blair, who initiated coverage with a valuation of $31 per share. The company is expected to reach three major clinical milestones in 2027 for its cancer treatments, olverembatinib and lisaftoclax, with estimated peak sales of $1.5 billion and $2.7 billion respectively. As of the latest report, Ascentage's stock was up 4.22% at $15.31. https://www.openbell.ai/news/EAT:1792173135652 2026-10-16T17:52:15.652Z daily 0.9 https://cdn.brandfetch.io/EAT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raymond James Upgrades Brinker International to Strong Buy, Lowers Price Target to $260 Raymond James analyst Brian Vaccaro has upgraded Brinker International (NYSE: EAT) from Outperform to Strong Buy. However, the price target has been lowered from $270 to $260. https://www.openbell.ai/news/CORZ:1792173124336 2026-10-16T17:52:04.336Z daily 0.9 https://cdn.brandfetch.io/CORZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Core Scientific shares are trading lower after Cantor Fitzgerald lowered its price target on the stock from $39 to $30. openbell Financial News https://www.openbell.ai/news/FRMI:1792172981520 2026-10-16T17:49:41.520Z daily 0.9 https://cdn.brandfetch.io/FRMI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Fermi shares are trading lower after Cantor Fitzgerald lowered its price target on the stock from $12 to $8. openbell Financial News https://www.openbell.ai/news/MCK:1792172790641 2026-10-16T17:46:30.641Z daily 0.9 https://cdn.brandfetch.io/MCK/w/400/h/400?c=1idopYfmtR7ZKg8QMud UBS Maintains Buy on McKesson, Raises Price Target to $1200 UBS analyst Kevin Caliendo has maintained a 'Buy' rating on McKesson (NYSE: MCK) and increased the price target from $1080 to $1200. This adjustment reflects positive expectations for the company's performance. https://www.openbell.ai/news/ONON:1792172747145 2026-10-16T17:45:47.145Z daily 0.9 https://cdn.brandfetch.io/ONON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raymond James Maintains Outperform on On Holding, Raises Price Target to $42 Raymond James analyst Rick Patel has maintained an 'Outperform' rating on On Holding (NYSE: ONON) and raised the price target from $38 to $42. This adjustment reflects a positive outlook for the company's performance. https://www.openbell.ai/news/FIVN:1792172517942 2026-10-16T17:41:57.942Z daily 0.9 https://cdn.brandfetch.io/FIVN/w/400/h/400?c=1idopYfmtR7ZKg8QMud UBS Maintains Buy on Five9, Raises Price Target to $48 UBS analyst Taylor McGinnis has maintained a Buy rating on Five9 (NASDAQ: FIVN) and increased the price target from $36 to $48. This adjustment reflects a positive outlook for the company's stock performance. https://www.openbell.ai/news/CAH:1792172417692 2026-10-16T17:40:17.692Z daily 0.9 https://cdn.brandfetch.io/CAH/w/400/h/400?c=1idopYfmtR7ZKg8QMud UBS Maintains Buy on Cardinal Health, Raises Price Target to $295 UBS analyst Kevin Caliendo has maintained a Buy rating on Cardinal Health (NYSE: CAH) and increased the price target from $280 to $295. This adjustment reflects a positive outlook for the company's stock performance. https://www.openbell.ai/news/QQQ:1792172373714 2026-10-16T17:39:33.714Z daily 0.9 https://cdn.brandfetch.io/QQQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Major indices are trading lower as rising Treasury yields and hotter-than-expected inflation data this week fuel a rotation out of tech and AI-related stocks. Credit risks tied to the AI infrastructure buildout are adding to the pressure, with the VanEck Semiconductor ETF (SMH) down 8% this week, on track for its biggest weekly decline since July. openbell Financial News https://www.openbell.ai/news/USO:1792172039803 2026-10-16T17:33:59.803Z daily 0.9 https://cdn.brandfetch.io/USO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oil is trading higher after reports suggesting that Iran placed its armed forced on high alert for 72 hours. Also, reports of an attempted Houthi strike on Saudi Arabia's Red Sea port of Yanbu and another Iranian strike on a vessel near the Strait of Hormuz are adding to concerns over marine energy transport risks. openbell Financial News https://www.openbell.ai/news/KVYO:1792170939043 2026-10-16T17:15:39.043Z daily 0.9 https://cdn.brandfetch.io/KVYO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Goldman Sachs Downgrades Klaviyo to Neutral, Lowers Price Target to $20 Goldman Sachs analyst Callie Valenti has downgraded Klaviyo (NYSE: KVYO) from a Buy rating to Neutral. The price target for the stock has been reduced from $27 to $20. https://www.openbell.ai/news/CBTO:1792170893456 2026-10-16T17:14:53.456Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/3d-Rendering-Of-Exchange-Traded-Fund-etf.jpg?width=250&height=187 EXCLUSIVE: Calamos Bitcoin ETF Upside Tops 40%: Top Exec Reveals the Catch Investors Can’t Ignore Calamos Investments' Bitcoin ETF, the Calamos Bitcoin 80 Series Structured Alt Protection ETF (CBTO), has an upside cap exceeding 40% for its one-year outcome period that began on October 7, 2023. This cap has increased from a gross starting rate of 36.22% due to a slight decline in Bitcoin's value. The ETF offers 80% downside protection, meaning investors are exposed to the first 20% of losses, while two other ETFs from Calamos provide varying levels of protection. Factors such as interest rates and options pricing influence the potential returns and caps of these ETFs. https://www.openbell.ai/news/NWG:1792170661304 2026-10-16T17:11:01.304Z daily 0.9 https://cdn.brandfetch.io/NWG/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'NatWest Group Withdrew Its Markets Securities Business From The Federal Reserve Bank Of New York’s List Of Primary Dealers As The Firm Pulls Back From U.S. And European Government Bond Markets, Effective Today' - Bloomberg News NatWest Group has officially withdrawn its markets securities business from the Federal Reserve Bank of New York's list of primary dealers, effective immediately. This decision marks the firm's strategic pullback from U.S. and European government bond markets. The move reflects a significant shift in NatWest's operations in these regions. https://www.openbell.ai/news/NWG:1792170617388 2026-10-16T17:10:17.388Z daily 0.9 https://cdn.brandfetch.io/NWG/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'NatWest Group Withdrew Its Markets Securities Business From The Federal Reserve Bank Of New York’s List Of Primary Dealers As The Firm Pulls Back From U.S. And European Government Bond Markets, Effective Today' - Bloomberg News openbell Financial News https://www.openbell.ai/news/OPK:1792170551202 2026-10-16T17:09:11.202Z daily 0.9 https://cdn.brandfetch.io/OPK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4 Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on OPKO Health (NASDAQ: OPK) and raised the price target from $3 to $4. This adjustment reflects a positive outlook for the company in the market.